company background image
20B

BioMark Diagnostics DB:20B Stock Report

Last Price

€0.19

Market Cap

€15.6m

7D

-3.6%

1Y

28.3%

Updated

12 Aug, 2022

Data

Company Financials
20B fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

20B Stock Overview

BioMark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment.

BioMark Diagnostics Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for BioMark Diagnostics
Historical stock prices
Current Share Price€0.19
52 Week High€0.23
52 Week Low€0.11
Beta0.68
1 Month Change-0.53%
3 Month Change40.91%
1 Year Change28.28%
3 Year Change186.60%
5 Year Change220.69%
Change since IPO-71.65%

Recent News & Updates

Shareholder Returns

20BDE BiotechsDE Market
7D-3.6%1.2%1.0%
1Y28.3%-0.5%-20.4%

Return vs Industry: 20B exceeded the German Biotechs industry which returned -2.5% over the past year.

Return vs Market: 20B exceeded the German Market which returned -20.5% over the past year.

Price Volatility

Is 20B's price volatile compared to industry and market?
20B volatility
20B Average Weekly Movement14.3%
Biotechs Industry Average Movement8.6%
Market Average Movement5.6%
10% most volatile stocks in DE Market10.2%
10% least volatile stocks in DE Market2.7%

Stable Share Price: 20B is more volatile than 90% of German stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: 20B's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
2014n/aRashid Ahmed Buxhttps://www.biomarkdiagnostics.com

BioMark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. It has a collaborative research agreement with the Icahn School of Medicine for clinical studies related to early lung cancer diagnosis. The company was incorporated in 2014 and is headquartered in Richmond, Canada.

BioMark Diagnostics Inc. Fundamentals Summary

How do BioMark Diagnostics's earnings and revenue compare to its market cap?
20B fundamental statistics
Market CapCA$20.52m
Earnings (TTM)-CA$1.45m
Revenue (TTM)CA$43.93k

469.3x

P/S Ratio

-14.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
20B income statement (TTM)
RevenueCA$43.93k
Cost of RevenueCA$0
Gross ProfitCA$43.93k
Other ExpensesCA$1.50m
Earnings-CA$1.45m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.017
Gross Margin100.00%
Net Profit Margin-3,309.36%
Debt/Equity Ratio-37.8%

How did 20B perform over the long term?

See historical performance and comparison